Thermo Fisher Enters into a Collaboration with Genome Canada and OICR to Develop NGS Assays for Cancer

 Thermo Fisher Enters into a Collaboration with Genome Canada and OICR to Develop NGS Assays for Cancer

Thermo Fisher Enters into a Collaboration with Genome Canada and OICR to Develop NGS Assays for Cancer

Shots:

  • Thermo Fischer signs a 3yrs. collaboration with Genome Canada and the Ontario Institute for Cancer Research (OICR) to develop targeted next-generation sequencing-based assays and analysis software for $6M. Genome to fund $2M for development & validation which will split b/w Thermo Fischer and OICR
  •  The partners will develop one assay for diagnosis of pancreatic cancer and two for prostate & breast cancer. Additionally, the assays will be used to stratify patients in clinical trials in Ontario and other jurisdictions following the previous collaboration of OICR and Thermo Fisher  
  • The NGS assays DNA & gene expression signatures from RNA providing an insight into cancer driver mutations. The collaboration will bring Thermo Fisher’s Ion Torrent technology across Canada  

Click here to­ read full press release/ article | Ref: Thermo Fisher| Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post